The European Commission (EC) has granted approval for the label extension of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in a combination regimen with ivacaftor.
This has been recommended for the treatment of CF in patients aged six to 11-years-old who have at least one F508del mutation in the CF transmembrane conductance regulator (CFTR) gene…